Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 12/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.34 |
| ▸ | SYK | P43405 | 2/20 | 0.34 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14789416 | 0.80 | CDK5 (0.42) | CPB2CDK5CDK5R1KDM2BMEN1 | |
| SCHEMBL15328886 | 0.77 | HDAC1 (0.49) | MEN1KMT2A | |
| SCHEMBL14789415 | 0.75 | CDK5 (0.44) | CPB2CDK5CDK5R1KDM2BMEN1 | |
| SCHEMBL14790042 | 0.75 | CDK5 (0.44) | CPB2CDK5CDK5R1MEN1ALDH1A1 | |
| SCHEMBL14789419 | 0.74 | CDK5 (0.45) | CPB2CDK5CDK5R1MEN1ALDH1A1 | |
| SCHEMBL15329204 | 0.74 | KDM5A (0.35) | CPB2CDK5CDK5R1SYKKDM5A | |
| SCHEMBL14789447 | 0.72 | CDK5 (0.36) | CDK5CDK5R1KDM2BMEN1ALDH1A1 | |
| SCHEMBL15329242 | 0.70 | CPB2 (0.38) | CPB2SYK | |
| SCHEMBL14631062 | 0.69 | CPB2 (0.43) | CPB2CDK5CDK5R1KDM2BKDM5A | |
| SCHEMBL12333257 | 0.69 | CPB2 (0.43) | CPB2CDK5CDK5R1KDM2BKDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2838895-B1 | AMINO-INDOLYL-SUBSTITUTED IMIDAZOLYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2016-07-13 | — | — | EP | disclosed |
| US-9096579-B2 | Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| EP-2838895-A1 | AMINO-INDOLYL-SUBSTITUTED IMIDAZOLYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2015-02-25 | — | — | EP | disclosed |
| WO-2013156608-A1 | AMINO-INDOLYL-SUBSTITUTED IMIDAZOLYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-24 | — | — | WO | disclosed |
| US-20130281430-A1 | Amino-Indolyl-Substituted Imidazolyl-Pyrimidines and Their Use as Medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281430-A1 | Amino-Indolyl-Substituted Imidazolyl-Pyrimidines and Their Use as Medicaments | INMT, IDO1, CHRM1 | CPB2 3424/4885CDK5 161/4885CDK5R1 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.